OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 28 ENHANCING OUR STRATEGIC PORTFOLIO BIOGEN 2021 YEAR IN REVIEW – BIIB801: Biogen and Xbrane Biopharma AB entered into a commercialization and license agreement to develop, manufacture and commercialize BIIB801 (Xcimzane™), a preclinical monoclonal antibody that is a proposed biosimilar referencing CIMZIA® (certolizumab pegol). CIMZIA’s primary indication is for RA in adults as well as axial spondylarthrosis, psoriasis and Crohn’s disease. Þ READ MORE ABOUT THE AGREEMENT We continue to generate new scientific insights, engaging 160,000 patients and producing 193 publications of Biogen- supported research since 2015. Our Biosimilars Medical Academy has attracted more than 410,000 individual site visitors since its launch in 2020. We also are working to further reduce any environmental impacts related to the full lifecycle of key Biogen biosimilars. Þ READ MORE IN THE ENVIRONMENT SECTION OF THIS REPORT Spotlighting biosimilars with IQVIA Institute In 2021, Biogen’s Ian Henshaw, Global Head of Biosimilars, co-hosted a webinar with IQVIA Institute for Human Data Science, inviting diverse stakeholders to discuss perspectives on the role of biosimilars in healthcare sustainability. The event built on IQVIA Institute’s report “Spotlight on Biosimilars: Optimizing the Sustainability of Healthcare Systems,” focusing on benefits of biosimilars that both expand earlier patient access to biologics and generate budget savings to balance the rising economic burdens on various healthcare systems. In 2020, the biologics market was valued at $320 billion, accounting for one-third of the value of the global pharmaceuticals market globally and 40% of the total market value in Europe. New launches are expected to increase from 13 new molecules per year (2014-2018) to 27 per year (2021-2025), presenting new opportunities and challenges. We believe the uptake of biosimilars is a key pillar of ensuring the sustainability of healthcare systems. Biosimilars stimulate competition within an established therapy area, reducing costs, broadening patient access and generating billions in healthcare savings for potential reinvestment in innovative therapies and diagnostic infrastructure. Digital Health At Biogen Digital Health, we aspire to transform patients’ lives and Biogen by making personalized and digital medicine in neuroscience a reality. Powered by data science and digital technologies, we drive solutions to advance research, clinical care and patient empowerment. We believe that now, more than ever, biology and technology should go hand in hand to better meet patient needs, while enabling a shift toward more prevention-focused, affordable and equitable care. In 2021, we continued to accelerate efforts to build complementary digital solutions and technologies to potentially predict, measure and prevent disease. With five digital solutions in the market and more in concept and development stages, we are actively exploring digital capabilities and solutions that are leverageable across our growing portfolio in areas such as digital biomarkers, personalized medicine, patient pathway improvement and digital therapeutics. Looking forward, we see the exciting opportunities to change lives by unlocking the impact of data and digital health across areas of strategic relevance to Biogen. Þ READ MORE IN THE PATIENTS SECTION OF THIS REPORT Collaborating for the greater good In 2021, a collaboration between Biogen, AbbVie and Pfizer launched access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease. Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 U.K. Biobank research participants. These genetic data have been paired with detailed health information, enabling scientists worldwide to use data for multiple areas of interest.